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Patients with autoimmune diseases (ADs) are a challenge for the intensivist; it is hard 
to differentiate among infection, disease activity, and combinations of both, leading to 
high mortality. This study is a retrospective analysis of 124 critically ill patients admit-
ted to the intensive care unit (ICU) in a university hospital between 2008 and 2016. 
Bivariate case–control analysis was performed, using patients who died as cases; later, 
analysis using a logistic regression model with variables that were associated with mor-
tality was conducted. Four variables were consistently associated with mortality in the 
logistic regression model and had adequate prediction value (Hosmer and Lemeshow 
statistic = 0.760; Nagelkerke R-squared = 0.494). The risk of death was found to be 
statistically associated with the following: shock at admission to ICU [odds ratio (OR): 
7.56; 95% confidence interval (CI): 1.78–31.97, p = 0.006], hemoglobin level <8 g/dL 
(OR: 16.12; 95% CI: 3.35–77.52, p = 0.001), use of cytostatic agents prior to admission 
to the ICU (OR: 8.71; 95% CI: 1.23–61.5, p = 0.03), and low levels ofcomplement C3 
(OR: 5.23; 95% CI: 1.28–21.35, p = 0.02). These variables can guide clinicians in the 
early identification of patients with AD with increased risk of death during hospitalization, 
leading to initial therapies seeking to improve survival. These results should be evaluated 
prospectively in future studies to establish their predictive power.
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inTrODUcTiOn
Autoimmune and rheumatological diseases are a challenge for the intensivist, given the usual multio-
rgan involvement, several comorbidities, the acute course of illness, and high mortality rates (37.5%) 
(1–3), as well as the lack of medical knowledge regarding the behavior of and clinical approach to 
these conditions in the intensive care unit (ICU).
Learning more about the characteristics of patients admitted with these diseases to the ICU, their 
management prior to admission to the unit, the cause that took them to the critical condition, the 
comorbidities, the frequency of association with infections, the management strategies used in the 
ICU, and identification of the organ systems more frequently involved could guide the intensivist 
2Carrizosa et al. Mortality in Patients with ADs in ICU
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 337
with reference to the interventions that improve the prognosis of 
this group of patients.
This study sought to determine the main factors associated 
with mortality in patients with autoimmune diseases (ADs) 
who were admitted to the ICU of the University Hospital of the 
Samaritana in Bogotá, Colombia, between January 2008 and 
February 2016.
MaTerials anD MeThODs
research Methodology
We conducted an observational, retrospective study based on a 
historic cohort, with patients with AD admitted to the ICU of the 
University Hospital of the Samaritana, along with a case–control 
nested analysis to determine the risk factors associated with 
mortality, given the low frequency of the disease in the general 
population.
study Population
All patients admitted to the ICU of the University Hospital of the 
Samaritana with a diagnosis of any AD between January 2008 
and February 2016 who were older than 16  years of age were 
considered for inclusion.
statistical analysis
On the basis of the results of a previous systematic review (4), 
in which the mortality rate for all causes in patients with AD 
varied between 17 and 55%, and considering that the prevalence 
of all AD as a whole to arrive at the ICU is unknown, a value of 
50% was assumed. In addition to the information available, an 
accuracy of 19% based on the results of the studies mentioned was 
considered. Variability in mortality in the ICU found by Quintero 
and the proportion of death in the study of Anton were close to 
this value (5). A sample of 45 patients was assumed for a statistical 
power of 80%, and a confidence level of 95% was applied to detect 
a statistical difference in the mortality between groups (survivors 
vs. no survivors).
Measures of central tendency (mean) and dispersion (SD) 
were used. Chi-square test for categorical variables and the 
Kolmogorov–Smirnov test for quantitative variables were applied 
in the bivariate analysis. Then, in a binary logistic regression 
model, the magnitude of association of the variables that showed 
a significant relationship in the bivariate analysis was determined, 
after categorization of the variables according to cutoff points that 
were considered clinically relevant; the weight of the association 
using odds ratio (OR) was determined.
ethical statement
This study was presented to and approved by the Ethics and 
Research Committee of the University Hospital of the Samaritana, 
in Act number 01, on June 7, 2013. According to international 
laws and the Declaration of Helsinki, as well as the ethical 
guidelines for biomedical research prepared by the Council for 
International Organizations of Medical Sciences (CIOMS), a risk 
that was lower than the minimum was established. No informed 
consent was needed.
resUlTs
Data from 124 patients were recorded, and the general character-
istics of the population were studied. We found that two-thirds 
(64%) of the patients were female, the mean age was 46.4 years 
(SD: ±19  years), and the most common AD was the systemic 
lupus erythematosus (SLE) (48.4%). Overlap syndromes were 
found at a frequency of 13%, which includes mainly overlap 
between SLE and antiphospholipid syndrome, and rheumatoid 
arthritis was found with a rate of 10%. Vasculitis was present in 
<6% of the cases. All the diagnostic criteria, including clinical, 
paraclinical, and immunological parameters, were met in 72% of 
the cases included.
The average duration of mechanical ventilation was 10 days 
(SD: ±13 days), and the length of stay in the ICU was 18 days 
(SD:  ±37  days). The average Acute Physiology and Chronic 
Health Evaluation (APACHE) II score at admission to the ICU 
was 20 points (SD: ±6 points).
The pulmonary involvement, as evaluated in the chest X-ray, 
showed that alveolar infiltration and consolidation occurred 
most frequently, followed by pleural effusion – by almost 30%, 
while the interstitial pattern was present in <9%.
The results in terms of the profiles of markers of autoimmunity 
showed that up to 90% of the patients had positive antinuclear 
antibodies, whereas only 26% were antineutrophil cytoplasmic 
antibody (ANCA)-positive; moreover, the anti-DNA titers were 
positive in 40% of patients. Levels of serum C3 and C4 were lower 
than the laboratory cutoff in 36 and 21%, respectively.
The kidney was the organ most frequently affected (60%), 
followed by the lung (41%) and neurological complications 
(36%), while involvement of the gastrointestinal, cardiovascu-
lar, and musculoskeletal systems was present in <30%. One-half 
of the patients showed shock at admission to the ICU (use of 
vasoactive drugs was determinant). The distributive type was 
the most frequent kind of shock. In Table  1, characteristics 
of organ involvement, medications, and severity are shown. 
All cases of secondary antiphospholipid syndrome associated 
with SLE were considered in the SLE group. The infection rate 
was high at ICU admission, with almost 50% in all AD cases, 
but rate of occurrence of pemphigus was 100%. Association 
between AD flares and infection was more frequent in SLE 
and antiphospholipid syndrome than in other ADs. The 
Systemic Lupus Erythematosus Disease Activity Index–Safety 
of Estrogens in Lupus Erythematosus National Assessment 
(SLEDAI–SELENA) score was applied to all patients with SLE 
to objectivize flares, and high severity was found in 26.7% 
(score ≥12). Mechanical ventilation in all groups of diseases 
was found to be particularly high, with an average of 72%. Acute 
heart failure was not infrequent; it was defined by contractility 
impairment with requirement for inotropic support. Acute 
renal injury with dialysis requirement was higher in SLE than in 
other ADs. However, nephritis was more frequent in vasculitis 
than in SLE patients.
Reentry to the unit was observed in 9% of patients, and 38% 
of patients died during their hospitalization in the ICU. Bivariate 
analysis between mortality and variables with significant correla-
tion are shown in Table 2. High correlation was found between 
TaBle 2 | Bivariate analysis and correlation with mortality in patients 
with aD.
Variable Pearson’s 
correlation
p-Value
Use of cytostatic agents before ICU admission 0.202a 0.026
Hemoglobin level ≤8 g/dL 0.256b 0.005
Pleural effusion 0.196a 0.031
Low level of complement C3 (<80 mg/dL) 0.292b 0.006
Low level of complement C4 (<12 mg/dL) 0.230a 0.037
APACHE II score ≥20 0.248a 0.035
Shock at ICU admission 0.405b 0.000
Serum procalcitonin >10 ng/mL 0.305b 0.001
Change in chronic immunosuppressive drugs 0.260b 0.005
Acidosis (pH ≤7.25) 0.218a 0.030
Positive antiphospholipid antibodies 0.409b 0.005
Acute heart failure 0.182a 0.049
Respiratory failure 0.306b 0.001
Bivariate analysis was performed, for evaluating the correlation between the outcome 
“mortality” and all the variables after dichotomization; only statistically significant results 
are shown.
aCorrelation was significant at the 0.05 level (two-tailed test).
bCorrelation was significant at the 0.01 level (two-tailed test).
TaBle 1 | characteristics of patients with aD differentiated by autoimmune condition, severity of illness, and organ injury.
Variable sle aPs ra gBs Vasculitis Pemphigus Other aDs
N 60 4 10 14 15 4 17
Female gender (%) 73.3 75 80 35.7 47.7 25 82.4
Prior use of steroids (%) 75 0 80 0 33 100 65
Prior use of cyclophosphamide (%) 18.3 0 20 0 26.7 0 0
ICU IVIG (%) 45 0 10 100 46.7 50 35.3
ICU plasmapheresis (%) 1.7 0 0 14.3 13.3 0 5.9
Flare of AD (%) 33.3 25 20 100 26.7 25 11.8
Infection (%) 48.3 50 30 50 40 100 47.1
Flare + infection (%) 23.3 25 10 21.4 6.7 25 11.8
APACHE II score ≥8 (%) 86.7 75 90 71.4 93.3 100 64.7
SLEDAI–SELENA score ≥12 (%) 26.7 N/A N/A N/A N/A N/A N/A
Shock at ICU admission (%) 56.7 75 80 28.6 53.3 25 41.2
Acute heart failure (%) 28.3 25 0 7.1 26.7 25 11.8
Hypoxemia (%) 40 50 42.9 33.3 50 50 33.3
Alveolar hemorrhage (%) 16.7 0 0 0 40 0 11.8
Pleural effusion (%) 31.7 25 10 7.1 6.7 25 5.9
Mechanical ventilation (%) 77.6 75 80 76.9 80 50 64.7
Mesenteric ischemia (%) 8.3 50 0 0 20 0 0
Convulsion (%) 10 0 0 0 13.3 25 5.9
Vasculitis CNS (%) 16.7 25 0 0 13.3 0 5.9
PNS involvement (%) 3.3 0 10 100 6.7 0 5.9
Nephritis (%) 16.7 0 0 0 26.7 25 11.8
Dialysis (%) 43.4 25 10 0 33.3 25 0
ICU mortality 40 50 40 35.7 40 50 29.4
SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; RA, rheumatoid arthritis; GBS, Guillaìn–Barré syndrome; AD, autoimmune disease; ICU, intensive care unit; 
IVIG, intravenous immunoglobulin; CNS, central nervous system; PNS, peripheral nervous system.
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mortality and the following factors: shock at ICU admission, pro-
calcitonin level >10 ng/mL, positive antiphospholipid antibodies, 
respiratory failure, and change in immunosuppression therapy. 
Other variables also had a good correlation, which was evaluated 
posteriorly for association with mortality by logistic regression.
A subgroup analysis for patients with SLE was performed. 
Association with mortality was found with alveolar hemorrhage, 
low complement C4, requirement for mechanical ventilation, and 
use of intravenous immunoglobulin. Other variables showed a 
trend with mortality, including shock at ICU admission, hemo-
globin level ≤8 g/dL, and severity scores, such as the APACHE II 
score ≥20 and the SLEDAI–SELENA score ≥12, as summarized 
in Table 3.
In the pooled logistic regression analysis (Table 4), statisti-
cally significant association was found between the outcome 
“mortality” and the following four variables: shock at admission 
to ICU [OR: 7.56; 95% confidence interval (CI): 1.78–31.97, 
p =  0.006], hemoglobin level <8  g/dL (OR: 16.12; 95% CI: 
3.35–77.52, p = 0.001), use of cytostatic agents prior to admis-
sion to the ICU (OR: 8.71; 95% CI: 1.23–61.5, p = 0.03), and 
low level ofcomplement C3 (OR: 5.23; 95% CI: 1.28–21.35, 
p  =  0.02), which had adequate prediction (Hosmer and 
Lemeshow statistic =  0.760; Nagelkerke R-squared =  0.494). 
In a previous analysis with 68 patients, a level of procalcitonin 
>10 ng/mL, serositis in the chest X-ray, and thrombocytopenia 
were also found to have an association with mortality. In the 
current regression model, the association was not significant; 
however, the presence of shock and complement C3 level were 
consistently associated with mortality. The variables with high 
SE were excluded from the model, as well as those that showed 
no significant association.
DiscUssiOn
ADs occur in <3% of the ICU admissions and have been 
described with greater frequency of multisystemic involvement 
caused by rheumatoid arthritis and vasculitis (1, 6). The most fre-
quent AD in this study was SLE. With regard to the demographic 
TaBle 4 | logistic regression analysis for predictors of in-hospital 
mortality.a
Variables Odds 
ratio
95% 
confidence 
interval
superior p-Value
inferior
Hemoglobin level ≤8 g/dL 16.1 3.4 77.5 0.001
Use of cytostatic agents prior to 
ICU admission
8.7 1.2 61.5 0.030
Shock at ICU admission 7.6 1.8 32.0 0.006
Low level ofcomplement C3 
(<80 mg/dL)
5.2 1.3 21.4 0.021
To evaluate the goodness of fit of the results in the bivariate analysis, a logistic 
regression was performed with multiple models, considering an adequate SE, as well 
as association with mortality, to discard potential confounding factors; the four variables 
with better performance are shown.
aOnly the variables with the best predictive model are shown.
Hosmer and Lemeshow goodness of fit: 0.760 (chi-square: 3.378; degrees of freedom: 6).
TaBle 3 | logistic regression analysis for subgroup systemic lupus 
erythematosus for the outcome “icU mortality”.
Variable Odds ratio 
(Or)
95% ci (Or) p-Value
inferior superior
Gender 2.500 0.697 8.971 0.16
SLEDAI score ≥12 3.643 0.938 14.153 0.062
Prior use of cytostatic agents 3.294 0.844 12.861 0.086
Prior use of steroids 1.462 0.429 4.979 0.544
Prior use of cyclophosphamide 2.067 0.551 7.747 0.282
ICU IVIG 6.314 2.013 19.804 0.002*
Hemoglobin ≤8 g/dL 3.000 0.999 9.010 0.05
Low level of complement C3 2.400 0.806 7.144 0.116
Low level of complement C4 3.693 1.192 11.441 0.024*
Infection 2.641 0.693 10.069 0.155
Flare + infection 1.167 0.347 3.924 0.803
APACHE II score ≥8 5.552 0.637 48.409 0.121
APACHE II score ≥20 3.575 0.872 14.649 0.077
Shock at ICU admission 3.200 0.966 10.603 0.054
Acute heart failure 1.500 0.482 4.669 0.484
Alveolar hemorrhage 4.529 0.038 19.771 0.045*
Nephritis 1.560 0.518 4.697 0.429
Dialysis 1.571 0.553 4.462 0.396
Procalcitonin level ≥10 ng/mL 3.000 0.899 10.007 0.074
Mechanical ventilation 11.478 1.375 95.826 0.024*
Variables with statistical association are marked with symbol *.
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characteristics, the findings were similar to those found by other 
researchers (2, 7–9), with majority of the patients being females 
and the mean age being 47 years (SD: ±19 years). The origin of the 
patient was also analyzed, patient population being of half urban 
and half rural origin.
The rate of ICU de novo diagnosis was 26.6%, which is close 
to what has been previously described in the literature (1). 
Considering the clinical presentation, the most frequently affected 
organ systems were the renal and pulmonary systems, similar to 
the results of Cavallasca et  al. (9), who indicated the existence 
of pulmonary manifestations of the disease, particularly at the 
cardiopulmonary level, as well as the synergy between respiratory 
tract infections and activity of the AD.
The cause of admission to the ICU could have different etiolo-
gies (8, 10, 11). In contrast with the findings of Ranzani et al. (12), 
who indicate that shock is the second cause of admission to the 
ICU after respiratory failure, with a distribution of 39 and 61%, 
respectively, in the population studied herein, shock was present 
in up to 60% of patients, but, the requirement for mechanical 
ventilation, as an indicator of respiratory failure, was notably 
high, correspondingly being the first cause of admission.
Infections were also present at greater frequency in this study. 
In Colombia, the incidence of infections in patients with AD in 
the ICU had already been described as 37.5% (13). However, it 
was found that the infections exceeded this number by >1.5 times 
(56%). The incidence of exacerbation of the disease or flare, in this 
study, was 27%, whereas Camargo et al. showed a flare frequency 
of 37.5%, with a similar reported rate of infections. Coexistence 
of flare and infection could also be present; in this study, we found 
a rate of 18% for this association, which did not differ from that 
reported in the literature (14).
Having evaluated the clinical severity measures, using the 
scales of prognosis, it was determined that the average APACHE 
II score was 19 points at the time of admission to the ICU, 
which is similar to that described in other publications (9, 15). 
In the SLE subgroup analysis, a severe flare was determined by 
a SLEDAI–SELENA score ≥12, which was found in 27% of the 
patients, with a trend to association with mortality.
In the study of Camargo et  al. (13), the need for invasive 
respiratory support was also reported, which was 54.2%. In the 
population being evaluated herein, the requirement for mechani-
cal ventilation was 82%; moreover, the duration for which these 
patients were ventilated were also measured (10 days); the need 
for reintubation was 4%.
Corticosteroids are frequently used in patients with AD (2, 
16–21). This study was not an exception, as the usual doses used 
by the patient were increased in all patients with exacerbation 
of the AD. Frequent use of immunoglobulins was also found, 
because this was applied to the 42.65% of the patients, who have 
already been described in several publications on the handling of 
flares, as an alternative to the high dose of other immunosuppres-
sive medications (22–24).
The prognosis of AD in the ICU depends on the initial severity 
of the pathology at the time of hospitalization. The first studies, 
conducted at the beginning of the 1990s sought to relate the 
severity of the disease with the forecast at the time of hospitaliza-
tion. Godeau et al. (14) included 69 patients with SLE, necrotizing 
vasculitis, AR, and other rheumatic diseases. The main reasons 
for admission were infections and acute exacerbation of the 
disease. The mortality rate was approximately 33%; Cruz et al., 
in 2003 (15), described the characteristics and prognostic factors 
in 29 patients with systemic necrotizing vasculitis, and the total 
mortality rate was 39%. Subsequently, Moreels et al., through a 
retrospective study, studying 71 patients admitted to the ICU for 
acute rheumatic diseases and 353 control patients (6), as well as 
Cruz et al., reported that the mortality rate was 39%. Recently, in 
2013, a systematic review conducted by Quintero et al. indicated 
that mortality in the ICU due to ADs has a broad range between 
17 and 55% when globally evaluated; the mortality in patients 
with SLE itself may reach 79% (4). In the current study, the 
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mortality rate was 40%; therefore, it could be argued that fatal 
outcomes are shown with a frequency similar to those described 
in other studies.
Finally, a multivariate analysis was performed with the goal 
of giving an answer to the general objective of this research and 
to determine if there are, in this population, factors related to 
mortality during the stay in the ICU of the University Hospital of 
the Samaritana. It was noted that there are significant differences 
between the vast majority of publications to date. Association 
among the presence of infection, AD activity, and coexistence 
between these two variables has been described with mortality, 
(1, 14, 25–28), as well as with high APACHE II scores (6, 9, 14, 
15). In contrast, in this study, an association of mortality with 
the presence of shock at admission, hemoglobin level <8 g/dL, 
the use of cytostatic drugs before admission to the ICU, and 
diminished levels of serum complement C3 was found. These 
factors to date have not been reported in the literature for the 
group of patients with rheumatologic disease who are admitted 
to the ICUs, except for the state of shock (12, 13). These findings 
generate new hypotheses and possibilities of research in this field, 
particularly in the search for a prospective form with the intention 
of validation of scales for mortality prediction aimed at earliest 
interventions and improvement in the prognosis of these patients.
cOnclUsiOn
Four risk factors associated with mortality were found: the 
presence of shock at admission to ICU, low level of complement 
C3, hemoglobin level <8 g/dL, and the use of cytostatic agents 
before admission to the ICU. Except for the presence of shock 
at admission to ICU, other factors have not been described with 
statistically significant association with mortality in this group of 
patients; therefore, this study can be a solid foundation for future 
research, and its results can provide a valuable clinical tool when 
evaluating patients with AD in the ICU.
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